[1]
Federico, C.; Morittu, V.M.; Britti, D.; Trapasso, E.; Cosco, D. Gemcitabine-loaded liposomes: Rationale, potentialities and future perspectives. Int. J. Nanomedicine, 2012, 7, 5423-5436.
[2]
Manjappa, A.S.; Goel, P.N.; Gude, R.P.; Murthy, R.S.R. Anti-neuropilin 1 antibody Fab′ fragment conjugated liposomal docetaxel for active targeting of tumours. J. Drug Target., 2014, 22(8), 698-711.
[3]
Manjappa, A.S.; Goel, P.N.; Vekataraju, M.P.; Rajesh, K.S.; Makwana, K.; Ukawala, M.; Nikam, Y.; Gude, R.P.; Murthy, R.S.R. Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond. Pharm. Res., 2013, 30(10), 2675-2693.
[4]
Urey, C.; Hilmersson, K.S.; Andersson, B.; Ansari, D.; Andersson, R. Development and in-vitro characterization of a gemcitabine-loaded MUC4-targeted immunoliposome against pancreatic ductal adenocarcinoma. Anticancer Res., 2017, 37(11), 6031-6039.
[5]
Ringhieri, P.; Mannucci, S.; Conti, G.; Nicolato, E.; Fracasso, G.; Marzola, P.; Morelli, G.; Accardo, A. Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Int. J. Nanomedicine, 2017, 12, 501-514.
[6]
Manjappa, A.S.; Chaudhari, K.R.; Venkataraju, M.P.; Dantuluri, P.; Nanda, B.; Sidda, C.; Sawant, K.K.; Murthy, R.S.R. Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J. Control. Release, 2011, 150(1), 2-22.
[7]
Elnakat, H.; Ratnam, M. Role of folate receptor genes in reproduction and related cancers. Front. Biosci., 2006, 11, 506-519.
[8]
Hilgenbrink, A.R.; Low, P.S. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci., 2005, 94, 2135-2146.
[9]
Kim, S.H.; Jeong, J.H.; Mok, H.; Lee, S.H.; Kim, S.W.; Park, T.G. Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN-PEG-folate conjugate and cationic lipids. Biotechnol. Prog., 2007, 23, 232-237.
[10]
Qiu, L.; Dong, C.; Kan, X. Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system. Drug Des. Devel. Ther., 2018, 12, 863-872.
[11]
Zhang, S.; Liu, Y.; Gan, Y.; Qiu, N.; Gu, Y.; Zhu, H. Conjugates of TAT and folate with DOX-loaded chitosan micelles offer effective intracellular delivery ability. Pharm. Dev. Technol., 2018, 24, 1-23.
[12]
Moghimipour, E.; Rezaei, M.; Ramezani, Z.; Kouchak, M.; Amini, M.; Angali, K.A.; Dorkoosh, F.A.; Handali, S. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil. Eur. J. Pharm. Sci., 2018, 114, 166-174.
[13]
Jain, A.; Jain, S.K. Advances in tumor targeted liposomes. Curr. Mol. Med., 2018, 18(1), 44-57.
[14]
Gazzano, E.; Rolando, B.; Chegaev, K.; Salaroglio, I.C.; Kopecka, J.; Pedrini, I.; Saponara, S.; Sorge, M.; Buondonno, I.; Stella, B.; Marengo, A.; Valoti, M.; Brancaccio, M.; Fruttero, R.; Gasco, A.; Arpicco, S.; Riganti, C. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors. J. Control. Release, 2018, 270, 37-52.
[15]
Kabilova, T.O.; Shmendel, E.V.; Gladkikh, D.V.; Chernolovskaya, E.L.; Markov, O.V.; Morozova, N.G.; Maslov, M.A.; Zenkova, M.A. Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes. Eur. J. Pharm. Biopharm., 2018, 123, 59-70.
[16]
Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6, 1949-1957.
[17]
Mamot, C.; Drummond, D.C.; Hong, K.; Kirpotin, D.B.; Park, J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updat., 2003, 6, 271-279.
[18]
Gemcitabine. USP DI. Volume 1. Drug information for the health care professional. Update monographs. Englewood, Colorado: Micromedex, Inc.; 18th October 1999.
[19]
Hertel, L.W.; Boder, G.B.; Kroin, J.S.; Rinzel, S.M.; Poore, G.A.; Todd, G.C.; Grindey, G.B. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine). Cancer Res., 1990, 50(14), 4417-4422.
[20]
Haran, G.; Cohen, R.; Bar, L.K.; Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta, 1993, 1151, 201-215.
[21]
Pan, X.G.; Zheng, X.; Shi, G.F.; Wang, H.Q.; Ratnam, M.; Lee, R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 2002, 100, 594-602.
[22]
Klibanov, A.L.; Maruyama, K.; Toechilin, V.P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 1990, 268, 235-237.
[23]
Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharma. Sci., 1994, 15, 215-220.
[24]
Manjappa, A.S.; Kumbhar, P.S.; Khopade, P.S.; Patil, A.B.; Disouza, J.I. Mixed micelles as nano polymer therapeutics of docetaxel: Increased in vitro cytotoxicity and decreased in vivo toxicity. Curr. Drug Deliv., 2018, 15(4), 564-575.
[25]
Richardson, V.J.; Jeyasingh, K.; Jewkes, R.F.; Ryman, B.E.; Tattersall, M.H. Properties of [99mTc] technetium-labeled liposomes in normal and tumour-bearing rats. Biochem. Soc. Trans., 1977, 5(1), 290-291.
[26]
Arulsudar, N.; Subramanian, N.; Mishra, P.; Chuttani, K.; Sharma, R.K.; Murthy, R.S.R. Preparation, characterization, and biodistribution study of technetium 99m labelled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice. AAPS PharmSci, 2004, 6(1), E5.
[27]
Snehalatha, M.; Venugopal, K.; Saha, R.N.; Babbar, A.K.; Sharma, R.K. Etoposide loaded PLGA and PCL nanoparticles II: Biodistribution and pharmacokinetics after radiolabelling with Tc-99m. Drug Deliv., 2008, 15(5), 277-287.
[28]
Reddy, L.H.; Sharma, R.K.; Chuttani, K.; Mishra, A.K.; Murthy, R.S.R. Etoposide incorporated tripalmitin nanoparticles with different surface charge: Formation, characterization, radiolabeling and biodistribution studies. AAPS J., 2004, 6(3), e23.
[29]
Patel, A.; Tyagi, A.; Sharma, R.K.; Thakkar, H. A gamma scintigraphy study to investigate uterine targeting efficiency of raloxifene-loaded liposomes administered intravaginally in New Zealand white female rabbits. Drug Deliv., 2016, 23(9), 3330-3338.
[30]
Pace, E.; Melis, M.; Siena, L.; Bucchieri, F.; Vignola, A.M.; Profita, M.; Gjomarkaj, M.; Bonsignore, G. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell-lung cancer (NSCLC) cell lines. Cancer Chemother. Pharmacol., 2000, 46, 467-476.
[31]
Hui, Y.; Reitz, J. Gemcitabine: A cytidine analog active against solid tumors. Am. J. Health Syst. Pharm., 1997, 54, 162-170.
[32]
Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 2006, 1(3), 297-315.
[33]
Affram, K.; Udofot, O.; Singh, M.; Krishnan, S.; Reams, R.; Rosenberg, J.; Agyare, E. Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS One, 2017, 12(9), e0185116.
[34]
Minh Le, V.; Nho, T.D.T.; Ly, H.T.; Sang Vo, T.; Nguyen, H.D.; Phung, T.T.H.; Zou, A.; Liu, J. Enhanced anticancer efficacy and tumor targeting through folate-PEG modified nanoliposome loaded with 5-fluorouracil. Adv. Nat. Sci.: Nanosci. Nanotechnol., 2017, 8 015008 (7pp)
[35]
Lohade, A.A.; Jain, R.R.; Iyer, K.; Roy, S.K.; Shimpi, H.H.; Pawar, Y.; Rajan, M.G.; Menon, M.D. A novel folate-targeted nanoliposomal system of doxorubicin for cancer targeting. AAPS PharmSciTech, 2016, 17(6), 1298-1311.
[36]
Xu, H.; Paxton, J.; Lim, J.; Li, Y.; Zhang, W.; Duxfield, L.; Wu, Z. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Pharm. Res., 2014, 31(10), 2583-2592.
[37]
Sriraman, S.K.; Pan, J.; Sarisozen, C.; Luther, E.; Torchilin, V. Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: In vitro evaluation on HeLa, A2780-ADR and H69-AR Cells. Mol. Pharm., 2016, 13(2), 428-437.
[38]
Majumdar, D.; Saha, C.N.; Bhattacharya, S. 99mTechnetium radiolebeling and biodistribution studies of some peptide based ligands. World J. Med. Sci, 2011, 6, 105-110.
[39]
Moustapha, M.E.; Shweeta, H.A.; Motaleb, M.A. Technetium-labeled danofloxacin complex as a model for infection imaging. Arab. J. Chem., 2016, 9(2), S1928-S1934.
[40]
Paolino, D.; Cosco, D.; Racanicchi, L.; Trapasso, E.; Celia, C.; Iannone, M.; Puxeddu, E.; Costante, G.; Filetti, S.; Russo, D.; Fresta, M. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: Biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Release, 2010, 144(2), 144-150.
[41]
Storniolo, A.M.; Allerheiligen, S.R.B.; Pearce, H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol., 1997, 24(2 suppl 7), S7-2-S7-7.
[42]
Reddy, L.H.; Couvreur, P. Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Des., 2008, 14, 1124-1137.
[43]
Pawar, H.; Surapaneni, S.K.; Tikoo, K.; Singh, C.; Burman, R.; Gill, M.S.; Suresh, S. Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats. Drug Deliv., 2016, 23(4), 1453-1468.
[44]
Li, X.; Wang, D.; Zhang, J.; Pan, W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J. Pharm. Pharmacol., 2009, 61, 1485-1492.
[45]
Gaber, M.; Medhat, W.; Hany, M.; Saher, N.; Fang, J.Y.; Elzoghby, A. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: Challenges and outcomes. J. Control. Release, 2017, 254, 75-91.
69
7
1